143 related articles for article (PubMed ID: 32610581)
1. Pimasertib Versus Dacarbazine in Patients With Unresectable
Lebbé C; Dutriaux C; Lesimple T; Kruit W; Kerger J; Thomas L; Guillot B; Braud F; Garbe C; Grob JJ; Loquai C; Ferraresi V; Robert C; Vasey P; Conry R; Isaacs R; Espinosa E; Schueler A; Massimini G; Dréno B
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32610581
[TBL] [Abstract][Full Text] [Related]
2. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Schadendorf D; Ascierto PA; Arance A; Dutriaux C; Di Giacomo AM; Rutkowski P; Del Vecchio M; Gutzmer R; Mandala M; Thomas L; Demidov L; Garbe C; Hogg D; Liszkay G; Queirolo P; Wasserman E; Ford J; Weill M; Sirulnik LA; Jehl V; Bozón V; Long GV; Flaherty K
Lancet Oncol; 2017 Apr; 18(4):435-445. PubMed ID: 28284557
[TBL] [Abstract][Full Text] [Related]
3. Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Lebbé C; Italiano A; Houédé N; Awada A; Aftimos P; Lesimple T; Dinulescu M; Schellens JHM; Leijen S; Rottey S; Kruse V; Kefford R; Raymond E; Faivre S; Pages C; Gomez-Roca C; Schueler A; Goodstal S; Massimini G; Delord JP
Target Oncol; 2021 Jan; 16(1):47-57. PubMed ID: 33211315
[TBL] [Abstract][Full Text] [Related]
4. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Arend RC; Davis AM; Chimiczewski P; O'Malley DM; Provencher D; Vergote I; Ghamande S; Birrer MJ
Gynecol Oncol; 2020 Feb; 156(2):301-307. PubMed ID: 31870556
[TBL] [Abstract][Full Text] [Related]
5. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
Hauschild A; Grob JJ; Demidov LV; Jouary T; Gutzmer R; Millward M; Rutkowski P; Blank CU; Miller WH; Kaempgen E; Martín-Algarra S; Karaszewska B; Mauch C; Chiarion-Sileni V; Martin AM; Swann S; Haney P; Mirakhur B; Guckert ME; Goodman V; Chapman PB
Lancet; 2012 Jul; 380(9839):358-65. PubMed ID: 22735384
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
[TBL] [Abstract][Full Text] [Related]
7. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
8. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Guo J; Carvajal RD; Dummer R; Hauschild A; Daud A; Bastian BC; Markovic SN; Queirolo P; Arance A; Berking C; Camargo V; Herchenhorn D; Petrella TM; Schadendorf D; Sharfman W; Testori A; Novick S; Hertle S; Nourry C; Chen Q; Hodi FS
Ann Oncol; 2017 Jun; 28(6):1380-1387. PubMed ID: 28327988
[TBL] [Abstract][Full Text] [Related]
10. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
Ascierto PA; Schadendorf D; Berking C; Agarwala SS; van Herpen CM; Queirolo P; Blank CU; Hauschild A; Beck JT; St-Pierre A; Niazi F; Wandel S; Peters M; Zubel A; Dummer R
Lancet Oncol; 2013 Mar; 14(3):249-56. PubMed ID: 23414587
[TBL] [Abstract][Full Text] [Related]
11. Meta-Analysis of the Safety and Efficacy of Interferon Combined With Dacarbazine Versus Dacarbazine Alone in Cutaneous Malignant Melanoma.
Xin Y; Huang Q; Zhang P; Yang M; Hou XY; Tang JQ; Zhang LZ; Jiang G
Medicine (Baltimore); 2016 Apr; 95(16):e3406. PubMed ID: 27100429
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.
Schadendorf D; Ugurel S; Schuler-Thurner B; Nestle FO; Enk A; Bröcker EB; Grabbe S; Rittgen W; Edler L; Sucker A; Zimpfer-Rechner C; Berger T; Kamarashev J; Burg G; Jonuleit H; Tüttenberg A; Becker JC; Keikavoussi P; Kämpgen E; Schuler G;
Ann Oncol; 2006 Apr; 17(4):563-70. PubMed ID: 16418308
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
[TBL] [Abstract][Full Text] [Related]
14. Dacarbazine combined targeted therapy versus dacarbazine alone in patients with malignant melanoma: a meta-analysis.
Jiang G; Li RH; Sun C; Liu YQ; Zheng JN
PLoS One; 2014; 9(12):e111920. PubMed ID: 25502446
[TBL] [Abstract][Full Text] [Related]
15. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomized study of dacarbazine, carmustine, cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients.
Chiarion Sileni V; Nortilli R; Aversa SM; Paccagnella A; Medici M; Corti L; Favaretto AG; Cetto GL; Monfardini S
Melanoma Res; 2001 Apr; 11(2):189-96. PubMed ID: 11333130
[TBL] [Abstract][Full Text] [Related]
19. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
20. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Hillner BE; Agarwala S; Middleton MR
J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
